XTL Biopharmaceuticals Ltd. XTLB
$ 1.9
2.7%
Annual report 2022
added 11-23-2024
XTL Biopharmaceuticals Ltd. Balance Sheet 2011-2024 | XTLB
Annual Balance Sheet XTL Biopharmaceuticals Ltd.
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | -3.29 M | -2.02 M | -3.82 M | -2.16 M | -2.89 M | -3.31 M | -123 K | |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 2.67 M | - | - | - | 11 K | 13 K | - |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 254 K | 232 K | 253 K | 2.97 M | 330 K | 436 K | 965 K | 1.23 M | 11.1 M | 629 K |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 35 K | - | - |
Retained Earnings |
- | - | -155 M | -154 M | -153 M | -156 M | -155 M | -152 M | -148 M | -146 M | -144 M | -143 M |
Total Assets |
4.19 M | 6.62 M | 6.5 M | 7.21 M | 8.58 M | 6.59 M | 3.02 M | 5.32 M | 5.64 M | 8.02 M | 11.1 M | 4.07 M |
Cash and Cash Equivalents |
2.09 M | 2.97 M | 3.63 M | 4.46 M | 3.26 M | 3.29 M | 2.02 M | 3.82 M | - | - | - | - |
Book Value |
- | 6.62 M | 6.25 M | 6.98 M | 8.32 M | 3.62 M | 2.69 M | 4.89 M | 4.68 M | 6.78 M | - | 3.44 M |
Total Shareholders Equity |
- | - | 3.61 M | 6.52 M | 7.27 M | 3.62 M | 2.69 M | 4.89 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet XTL Biopharmaceuticals Ltd.
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | -155 M | - | -156 M | - | -156 M | - | - | - | -153 M | - | - | - | -153 M | - | - | - | -156 M | - | - | - | -155 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 6.62 M | - | 6.95 M | - | 6.5 M | - | - | - | 7.21 M | - | - | - | 8.58 M | - | - | - | 6.59 M | - | - | - | 3.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 2.97 M | - | 2.92 M | - | 3.63 M | - | 4.03 M | - | 4.46 M | - | - | - | 3.26 M | - | - | - | 3.29 M | - | - | - | 2.02 M | - | - | - | 3.82 M | - | - | - | 2.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 6.62 M | - | 6.95 M | - | 6.5 M | - | - | - | 7.21 M | - | - | - | 8.58 M | - | - | - | 6.59 M | - | - | - | 3.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 5.33 M | - | 3.28 M | 4.37 M | 3.61 M | - | 5.6 M | 6.71 M | 6.52 M | - | - | - | 7.27 M | - | - | - | 3.62 M | - | - | - | 2.69 M | - | - | - | 4.89 M | - | - | - | 4.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency